Chemical-structure (Pemetrexed 01)
Pemetrexed Injection, Solution
Product Images NDC 0781-3518
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 0781-3518). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Pemetrexed 02)
This is a chart showing the number of participants at risk over time in months for two different treatment arms, A+P+C and A+C. A+P+C refers to treatment with pemetrexed, pembrolizumab, and platinum chemotherapy while A+C refers to treatment with pemetrexed, platinum chemotherapy, and placebo.*
Figure2 (Pemetrexed 03)
This is a graph representing the survival probability over time for two treatments: Pemetrexed + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The x-axis shows the survival time in months and the y-axis shows the survival probability. The graph also includes a table with the number of patients at risk for both treatments.*
Figure3 (Pemetrexed 04)
This appears to be a table or figure showing survival time for patients receiving different chemotherapy treatments (pemetrexed and cisplatin, or gemcitabine and cisplatin) over a course of 27 months. The numbers beneath each treatment indicate the number of patients still at risk at each time point.*
Figure4 (Pemetrexed 05)
This looks like data related to chemotherapy drugs Pemetrexed + Cisplatin (AC) and Gemcitabine + Cisplatin (6C) for cancer treatment. The data shows the survival time in months for patients receiving either of the two drug combinations. The document provides a table representing the patients at risk for both treatments.*
Figure5 (Pemetrexed 06)
This is a survival curve for two treatments (Pemetrexed vs Placebo) over a period of 42 months. The X-axis shows the survival time in months and the Y-axis shows the number of patients at risk. The blue line represents the survival curve of patients receiving Pemetrexed, and the orange line represents the survival curve of patients receiving Placebo. The graph shows that patients receiving Pemetrexed had a longer survival time than those receiving Placebo.*
Figure6 (Pemetrexed 07)
Figure7 (Pemetrexed 08)
This appears to be a survival analysis chart comparing the survival probability of patients receiving Pemetrexed against those receiving a placebo. The chart provides the number of patients at risk for each treatment at different time intervals (in months), and the corresponding number of patients who survived. It also includes a graph showing the survival time (in months) for both groups.*
Figure8 (Pemetrexed 09)
This is a survival probability graph that shows the survival time of patients who were given Pemetrexed and Placebo over a period of 36 months. The horizontal axis represents the survival time in months and the vertical axis represents the survival probability. The graph suggests that patients who were given Pemetrexed had a higher survival probability compared to those who were given Placebo. The number of patients at risk and their survival time in months are also indicated.*
Figure9 (Pemetrexed 10)
100mg-carton (Pemetrexed 11)
This is a description of a medication called Pemetrexed Injection. This medication is a cytotoxic agent and should only be administered through intravenous infusion. It comes in a single-dose vial with a strength of 100 mg/4 mL. It should be discarded if unused. Pemetrexed injection should be stored at 25°C, protected from light and kept in the carton box until the moment of use. Each mL contains 25.0 mg of pemetrexed, 0.5 mg of sodium thiosulfate pentahydrate, 50.0 mg of propylene glycol, and water for injection. The dosage and dilution must be followed as per prescribing information.*
500mg-carton (Pemetrexed 12)
Pemeirexed is a cytotoxic agent administered as an injection for intravenous infusion after dilution. The single-dose vial contains 500mg/20mL of Pemeirexed with 25 mg/mL concentration. Each mL contains 25.0 mg pemetrexed, 0.5 mg of sodium thiosulfate pentahydrate, 50.0 mg propylene glycol, and water for injection. The recommended dosage and instructions for dilution can be found in the prescribing information. The solution should be stored at controlled room temperature, protected from light, and discarded if unused. The NDC codes for this product are 0781-3519-20 and 0761-3519-60.*
1000mg-carton (Pemetrexed 13)
This is a medication called Pemetrexed, which is a cytotoxic agent used for intravenous (IV) infusion after dilution. Each vial contains 1,000 mg/40 mL (25 mg/ml) of Pemetrexed. The medication should be discarded if not completely used after dilution. It should be stored at 25°C (77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The recommended dosage is 1,000 mg/40 mL and it should be diluted with 0.9% Sodium Chloride Injection to a total volume of 100 mL for IV infusion. Full dilution information should be obtained from the prescribing information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
